Cargando…

Immunosuppressive capacity of circulating MDSC predicts response to immune checkpoint inhibitors in melanoma patients

PURPOSE: Although the treatment of advanced melanoma patients with immune checkpoint inhibitors (ICI) significantly increased the therapeutic efficiency, many patients remain resistant to ICI that could be due to immunosuppression mediated by myeloid-derived suppressor cells (MDSC). These cells are...

Descripción completa

Detalles Bibliográficos
Autores principales:	Petrova, Vera, Groth, Christopher, Bitsch, Rebekka, Arkhypov, Ihor, Simon, Sonja C. S., Hetjens, Svetlana, Müller, Verena, Utikal, Jochen, Umansky, Viktor
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9968744/ https://www.ncbi.nlm.nih.gov/pubmed/36860876 http://dx.doi.org/10.3389/fimmu.2023.1065767

Ejemplares similares

Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma
por: Petrova, Vera, et al.
Publicado: (2020)

IL-6 regulates CCR5 expression and immunosuppressive capacity of MDSC in murine melanoma
por: Weber, Rebekka, et al.
Publicado: (2020)

STAT3 inhibitor Napabucasin abrogates MDSC immunosuppressive capacity and prolongs survival of melanoma-bearing mice
por: Bitsch, Rebekka, et al.
Publicado: (2022)

Melanoma patients with immune-related adverse events after immune checkpoint inhibitors are characterized by a distinct immunological phenotype of circulating T cells and M-MDSCs
por: Lepper, Alisa, et al.
Publicado: (2023)

HSP90α induces immunosuppressive myeloid cells in melanoma via TLR4 signaling
por: Arkhypov, Ihor, et al.
Publicado: (2022)

Myeloid Cell Modulation by Tumor-Derived Extracellular Vesicles
por: Arkhypov, Ihor, et al.
Publicado: (2020)

Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target
por: Ozbay Kurt, Feyza Gul, et al.
Publicado: (2023)

Blocking Migration of Polymorphonuclear Myeloid-Derived Suppressor Cells Inhibits Mouse Melanoma Progression
por: Groth, Christopher, et al.
Publicado: (2021)

The Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression
por: Umansky, Viktor, et al.
Publicado: (2016)

Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression
por: Groth, Christopher, et al.
Publicado: (2018)

Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression
por: Fleming, Viktor, et al.
Publicado: (2018)

Booster dose of mRNA vaccine augments waning T cell and antibody responses against SARS-CoV-2
por: Özbay Kurt, Feyza Gül, et al.
Publicado: (2022)

Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors
por: Weber, Rebekka, et al.
Publicado: (2018)

Eosinophil accumulation predicts response to melanoma treatment with immune checkpoint inhibitors
por: Simon, Sonja C. S., et al.
Publicado: (2020)

HER3-Receptor-Mediated STAT3 Activation Plays a Central Role in Adaptive Resistance toward Vemurafenib in Melanoma
por: Hüser, Laura, et al.
Publicado: (2020)

New strategies for melanoma immunotherapy: How to overcome immunosuppression in the tumor microenvironment
por: Umansky, Viktor
Publicado: (2012)

Enhanced expression of CD39 and CD73 on T cells in the regulation of anti-tumor immune responses
por: Shevchenko, Ivan, et al.
Publicado: (2020)

MDSC in Mice and Men: Mechanisms of Immunosuppression in Cancer
por: Vanhaver, Christophe, et al.
Publicado: (2021)

Leukocyte Count Restoration Under Dabrafenib Treatment in a Melanoma Patient With Vemurafenib-Induced Leukopenia: Case Report
por: Orouji, Elias, et al.
Publicado: (2014)

Critical immunosuppressive effect of MDSC-derived exosomes in the tumor microenvironment
por: Rashid, Mohammad H., et al.
Publicado: (2021)

Identification of an Immature Subset of PMN-MDSC Correlated to Response to Checkpoint Inhibitor Therapy in Patients with Metastatic Melanoma
por: Gondois-Rey, Françoise, et al.
Publicado: (2021)

Case report: Therapeutic potential of T-VEC in combination with MEK inhibitors in melanoma patients with NRAS mutation
por: Simon, Sonja C. S., et al.
Publicado: (2023)

ADCK2 Knockdown Affects the Migration of Melanoma Cells via MYL6
por: Vierthaler, Marlene, et al.
Publicado: (2022)

Mithramycin A and Mithralog EC-8042 Inhibit SETDB1 Expression and Its Oncogenic Activity in Malignant Melanoma
por: Federico, Aniello, et al.
Publicado: (2020)

Differential expansion of circulating human MDSC subsets in patients with cancer, infection and inflammation
por: Cassetta, Luca, et al.
Publicado: (2020)

Neutrophils in Tumorigenesis: Missing Targets for Successful Next Generation Cancer Therapies?
por: Tolle, Fabrice, et al.
Publicado: (2021)

Overcoming immunosuppression as a new immunotherapeutic approach against pancreatic cancer
por: Bazhin, Alexandr V, et al.
Publicado: (2013)

Long non-coding RNA RUNXOR accelerates MDSC-mediated immunosuppression in lung cancer
por: Tian, Xinyu, et al.
Publicado: (2018)

CHBP induces stronger immunosuppressive CD127(+) M-MDSC via erythropoietin receptor
por: Li, Jiawei, et al.
Publicado: (2021)

GTN Enhances Antitumor Effects of Doxorubicin in TNBC by Targeting the Immunosuppressive Activity of PMN-MDSC
por: Mabrouk, Nesrine, et al.
Publicado: (2023)

Melanoma-Derived iPCCs Show Differential Tumorigenicity and Therapy Response
por: Bernhardt, Mathias, et al.
Publicado: (2017)

Targeting MDSC for Immune-Checkpoint Blockade in Cancer Immunotherapy: Current Progress and New Prospects
por: Li, Tianhang, et al.
Publicado: (2021)

Myeloid-Derived Suppressor Cells Interact with Tumors in Terms of Myelopoiesis, Tumorigenesis and Immunosuppression: Thick as Thieves
por: Sevko, Alexandra, et al.
Publicado: (2012)

The role of hypoxia in shaping the recruitment of proangiogenic and immunosuppressive cells in the tumor microenvironment
por: Chouaib, Salem, et al.
Publicado: (2018)

Tadalafil has biologic activity in human melanoma. Results of a pilot trial with Tadalafil in patients with metastatic Melanoma (TaMe)
por: Hassel, Jessica C., et al.
Publicado: (2017)

BTK Inhibition Reverses MDSC-Mediated Immunosuppression and Enhances Response to Anti-PDL1 Therapy in Neuroblastoma
por: Ishfaq, Mehreen, et al.
Publicado: (2021)

Melanoma Cellular Plasticity
por: Novak, Daniel, et al.
Publicado: (2022)

ADP secreted by dying melanoma cells mediates chemotaxis and chemokine secretion of macrophages via the purinergic receptor P2Y12
por: Kloss, Loreen, et al.
Publicado: (2019)

Genetic screen in myeloid cells identifies TNF-α autocrine secretion as a factor increasing MDSC suppressive activity via Nos2 up-regulation
por: Schröder, Matthias, et al.
Publicado: (2018)

Loss of tumorigenic potential upon transdifferentiation from keratinocytic into melanocytic lineage
por: Fehrenbach, Sabrina, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_1fdabi2eiik2fh1al3619h7lca